A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products

Abstract

Background: Pharmacological management of chronic neuropathic pain (CNP) still represents a major clinical challenge. Collective harnessing of both the scientific evidence base and clinical experience (of clinicians and patients) can play a key role in informing treatment pathways and contribute to the debate on specific treatments (e.g., cannabinoids). A group of expert clinicians (pain specialists and psychiatrists), scientists, and patient representatives convened to assess the relative benefit-safety balance of 12 pharmacological treatments, including orally administered cannabinoids/cannabis-based medicinal products, for the treatment of CNP in adults. Methods: A decision conference provided the process of creating a multicriteria decision analysis (MCDA) model, in which the group collectively scored the drugs on 17 effect criteria relevant to benefits and safety and then weighted the criteria for their clinical relevance. Findings: Cannabis-based medicinal products consisting of tetrahydrocannabinol/cannabidiol (THC/CBD), in a 1:1 ratio, achieved the highest overall score, 79 (out of 100), followed by CBD dominant at 75, then THC dominant at 72. Duloxetine and the gabapentinoids scored in the 60s, amitriptyline, tramadol, and ibuprofen in the 50s, methadone and oxycodone in the 40s, and morphine and fentanyl in the 30s. Sensitivity analyses showed that even if the pain reduction and quality-of-life scores for THC/CBD and THC are halved, their benefit-safety balances remain better than those of the noncannabinoid drugs. Interpretation: The benefit-safety profiles for cannabinoids were higher than for other commonly used medications for CNP largely because they contribute more to quality of life and have a more favorable side effect profile. The results also reflect the shortcomings of alternative pharmacological treatments with respect to safety and mitigation of neuropathic pain symptoms. Further high-quality clinical trials and systematic comprehensive

Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study

“…However, long-term opioid treatment in non-specific pain patients delivered good pain relief in only 51% of patients ( 37 ). Although Cochrane review of neuropathic pain treated with cannabis-based medicines against placebo, found a modest gain from 16 studies ( n = 1,750) with 21 vs. 17% achieving a 50% reduction in pain; and 39 vs. 33% achieving a 30% reduction ( 46 ), a multiple-criteria decision analysis found that the benefit-safety profiles for cannabinoids were higher than for other commonly used medications for chronic neuropathic pain largely because they contribute more to QOL and have a more favorable side-effect profile ( 47 ). Furthermore, for patients with chronic pain, opioids may contribute to substantial functional impairment ( 48 ), so serious adverse effects of opioids may limit effectiveness in some patients, even if adequate analgesia is achieved ( 48 ).…”

Promising Health Benefits of Adjuvant Acmella and Zingiber Extracts Combined with Coenzyme Q10 Phytosomes, Supplementation in Chronic Pain Treated with Medical Cannabis: A Prospective and Open-Label Clinical Study

“…However, due to side effects and a low efficacy, the pain intensity remains of considerable clinical importance. The discovery of the crucial role of the endocannabinoid system in pain opened new therapeutic perspectives [ 20 , 21 ], and the introduction of cannabis therapy for chronic pain has been successful [ 3 , 22 ], as demonstrated by several studies [ 23 – 26 ]. Medical cannabis products were recently well-summarized by Brunetti et al [ 5 ], with the rationale to help doctors with dosing and titration strategies for THC and CBD preparations.…”

Δ9–Tetrahydrocannabinol (THC)-Rich Compositions from Cannabis Have Cytotoxic Activity Against Ovarian Cancer Cells and Act Synergistically With Niraparib in vitro

“…Our results indicate that cannabis might be regarded as a complementary and effective anti-cancer treatment for OC. Given the favorable safety profile of phytocannabinoids compared to standard pharmacotherapy (e.g., [34]), we propose that clinical trials with cannabis-based products are needed desperately for OC patients. the manuscript.…”